Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329393 | 1.00 | BCHE (0.41) | BCHEACHEBACE1TMEM97SIGMAR1 | |
| SCHEMBL4331380 | 1.00 | BCHE (0.41) | BCHEACHEBACE1TMEM97SIGMAR1 | |
| SCHEMBL4329387 | 1.00 | BCHE (0.41) | BCHEACHEBACE1TMEM97SIGMAR1 | |
| SCHEMBL4327749 | 0.93 | MAOB (0.44) | BCHEACHEBACE1TMEM97SIGMAR1 | |
| SCHEMBL4322290 | 0.93 | MAOB (0.44) | BCHEACHEBACE1TMEM97SIGMAR1 | |
| SCHEMBL4327756 | 0.93 | MAOB (0.44) | BCHEACHEBACE1TMEM97SIGMAR1 | |
| SCHEMBL4329139 | 0.93 | MAOB (0.44) | BCHEACHEBACE1TMEM97SIGMAR1 | |
| SCHEMBL4328848 | 0.90 | TMEM97 (0.46) | BCHEACHEBACE1TMEM97SIGMAR1 | |
| SCHEMBL13611881 | 0.90 | TMEM97 (0.46) | BCHEACHEBACE1TMEM97SIGMAR1 | |
| SCHEMBL4328846 | 0.90 | TMEM97 (0.46) | BCHEACHEBACE1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | BCHE 2634/4885ACHE 2128/4885BACE1 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.